emerg
coronavirus
cov
primarili
caus
sever
gastroenter
respiratori
diseas
human
anim
approv
therapeut
current
avail
receptor
tyrosin
kinas
inhibitor
rtki
tyrphostin
class
identifi
robust
inhibitor
transmiss
gastroenter
viru
tgev
infect
cellbas
assay
moreov
exhibit
potent
antivir
activ
replic
variou
cov
includ
murin
hepat
viru
mhv
porcin
epidem
diarrhea
viru
pedv
felin
infecti
periton
viru
fipv
perform
compar
phosphoproteom
analysi
investig
mechan
action
tgev
infect
vitro
specif
identifi
downstream
molecul
receptor
tyrosin
kinas
rtk
requir
effici
tgev
replic
target
plaqu
assay
qrtpcr
western
blot
assay
inhibitor
rna
interfer
show
inhibitori
activ
tgev
infect
mainli
mediat
mitogenactiv
protein
kinas
mapk
signal
pathway
find
indic
rtki
directli
inhibit
tgev
replic
inhibitori
activ
tgev
replic
mainli
occur
target
provid
vital
clue
design
novel
drug
cov
coronavirus
cov
envelop
virus
possess
singlestrand
positivesens
rna
genom
belong
famili
coronavirida
order
nidoviral
cov
genom
current
largest
known
viral
rna
genom
total
length
kb
cov
consist
four
genera
alpha
beta
gamma
tent
new
genu
deltacoronaviru
de
groot
et
al
cov
commonli
caus
gastroenter
respiratori
diseas
anim
host
well
human
given
current
approv
vaccin
antivir
strategi
mani
pathogen
cov
ramajayam
et
al
increasingli
import
identifi
broadspectrum
antivir
compound
compound
promot
quick
respons
threat
new
chang
pandem
possibl
even
without
accur
identif
agent
transmiss
gastroenter
viru
tgev
caus
agent
porcin
transmiss
gastroenter
togeth
porcin
epidem
diarrhea
viru
pedv
human
cov
canin
cov
ccov
belong
alpha
coronaviru
carsten
tgev
caus
fatal
acut
diarrhea
vomit
dehydr
mortal
rate
nearli
suckl
piglet
less
week
old
pritchard
et
al
result
sever
econom
loss
swine
industri
worldwid
approxim
twothird
region
tgev
genom
encod
replicas
gene
rep
contain
two
open
read
frame
polyprotein
polyprotein
ab
translat
rep
gorbalenya
et
al
proteolyt
process
virusencod
proteas
nonstructur
protein
nsp
nsp
mani
enzymat
activ
papainlik
proteas
plp
proteas
rnadepend
rna
polymeras
rdrp
helicas
nsp
along
put
cellular
factor
believ
form
replicationtranscript
complex
play
import
role
cov
rna
transcript
replic
neuman
et
al
crystal
structur
larg
number
viral
nonstructur
structur
protein
solv
target
drug
design
attempt
tong
unfortun
effort
led
advanc
antivir
drug
beyond
preclin
stage
hilgenfeld
peiri
overal
targetbas
approach
ignor
possibl
target
includ
host
cell
signal
pathway
host
factor
essenti
cov
replic
furthermor
rna
viral
genom
typic
replic
low
fidel
undergo
rapid
evolutionari
chang
thu
target
cellular
factor
involv
viru
infect
provid
excel
strategi
drug
develop
treatment
easili
evad
high
mutat
rate
viral
genom
zhou
et
al
protein
kinas
phosphatas
involv
wide
varieti
cellular
function
receptor
tyrosin
kinas
rtk
group
growth
factor
receptor
key
compon
biolog
control
network
regul
mani
biolog
process
includ
cell
prolifer
differenti
well
surviv
lemmon
schlessing
rtk
also
play
import
role
transform
extracellular
intracellular
signal
activ
link
downstream
signal
pathway
rasmitogenactiv
protein
kinas
mapk
jakstat
pathway
pawson
schlessing
rtk
master
regul
normal
cellular
process
play
vital
role
develop
progress
variou
cancer
extens
studi
target
treatment
mani
type
malign
roussidi
karamano
recent
grow
number
studi
shown
sever
rtk
tyrosin
kinas
involv
viral
replic
exampl
receptor
tyrosin
kinas
axl
function
entri
factor
dengu
viru
zika
viru
zikv
meerten
et
al
meerten
et
al
addit
protein
tyrosin
kinas
inhibitor
genistein
shown
block
replic
human
immunodefici
viru
herp
simplex
viru
type
arenavirus
stantchev
et
al
vela
et
al
yura
et
al
protein
tyrosin
phosphatas
also
shown
target
antivir
therapi
carbon
et
al
imatinib
abelson
abl
kinas
inhibitor
shown
potent
inhibitor
sarscov
merscov
vitro
dyall
et
al
two
rtk
inhibitor
rtki
known
tyrphostin
block
multipl
step
influenza
viru
replic
underli
mechan
inhibitori
effect
target
unclear
kumar
et
al
kumar
et
al
rafmekerk
pathway
downstream
rtk
involv
murin
hepat
viru
mhv
rna
synthesi
cai
et
al
recent
studi
indic
epiderm
growth
factor
receptor
egfr
promot
tgev
entri
hu
et
al
current
studi
use
model
alphacoronaviru
tgev
screen
inhibitor
cov
replic
use
highthroughput
assay
base
pronounc
cytopath
effect
cpe
caus
tgev
infect
cell
identifi
tyrphostin
specif
rtki
strong
antivir
activ
tgev
addit
appear
broadspectrum
cov
inhibitor
block
replic
mhv
pedv
felin
infecti
periton
viru
fipv
compar
efficaci
furthermor
employ
pharmacolog
inhibitor
rna
interfer
demonstr
dramat
suppress
viral
replic
viral
rna
synthesi
mainli
signal
pathway
find
provid
molecular
insight
potenti
role
host
rtk
signal
pathway
promot
replic
cov
suggest
tyrphostin
could
develop
potenti
anticov
therapi
st
african
green
monkey
kidney
epitheli
cell
cat
kidney
epitheli
cell
maintain
co
incub
dulbecco
modifi
eagl
medium
dmem
invitrogen
carlsbad
ca
usa
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
unitsml
fipv
purchas
american
type
cultur
collect
manassa
va
usa
pedv
strain
genbank
access
number
tgev
strain
genbank
access
number
isol
suckl
piglet
pedv
fipv
propag
cell
respect
tgev
grown
st
cell
viral
titer
determin
plaqu
assay
tgev
pedv
fipv
cell
infect
cultur
cell
pedv
conduct
presenc
trypsin
concentr
serumfre
medium
librari
pharmacolog
activ
compound
lopac
purchas
sigmaaldrich
compound
dissolv
mm
dimethyl
sulfoxid
dmso
store
tyrphostin
ribavirin
flunarizin
purchas
sigma
inhibitor
inhibitor
obtain
apexbio
purchas
targetmol
gapdhspecif
monoclon
antibodi
purchas
proteintech
chicago
il
usa
antibodi
junntermin
kinas
jnk
phosphoryl
phosphoryl
jnk
pjnk
purchas
cell
signal
technolog
washington
dc
usa
antiphosphoryl
antibodi
specif
antitgev
n
polyclon
antibodi
prepar
laboratori
tyrphostin
store
mm
stock
solut
dmso
store
mm
stock
solut
dmso
cytotox
effect
reagent
cell
viabil
measur
plate
use
celltiterglo
promega
accord
manufactur
protocol
cell
viabil
determin
use
verita
micropl
luminomet
promega
valu
normal
untreat
cell
accordingli
throughout
work
cytotox
observ
effect
infect
tgev
st
cell
pedv
vero
cell
fipv
cell
mhv
cell
determin
compar
level
viral
replic
target
cell
absenc
presenc
target
cell
pretreat
triplic
dmso
h
follow
viru
infect
multipl
infect
moi
cell
supernat
harvest
h
post
infect
hpi
viral
titer
quantifi
plaqu
format
assay
assess
effect
inhibitor
jnk
tgev
cell
infect
tgev
treat
dmso
cultur
supernat
collect
differ
time
point
hpi
store
tgev
titer
determin
plaqu
assay
use
cell
describ
previous
quantifi
plaqueform
unit
pfu
per
ml
antivir
mechan
determin
timeofaddit
assay
previous
describ
basu
et
al
procedur
shown
schemat
fig
cell
infect
tgev
moi
h
h
ad
cell
h
preinfect
h
infect
h
h
postinfect
h
exclud
possibl
direct
inactiv
effect
tgev
viru
w
dong
et
al
antivir
research
incub
h
mixtur
use
infect
cell
h
duplic
well
use
process
cell
cultur
treat
drug
vehicl
dmso
use
control
hpi
cultur
medium
harvest
viru
titrat
sampl
use
quantit
proteom
analysi
consist
four
group
cell
infect
moi
tgev
uninfect
cell
treat
uninfect
cell
treat
dmso
cell
infect
tgev
treat
hpi
cell
collect
protein
extract
digest
label
cell
sampl
four
group
collect
cell
scraper
wash
twice
icecold
phosphatebuff
salin
pb
contain
proteas
inhibitor
cocktail
cell
lyse
lysi
buffer
remain
debri
remov
centrifug
min
supernat
collect
protein
concentr
determin
bicinchonin
acid
bca
kit
accord
manufactur
instruct
trypsin
ad
protein
solut
trypsintoprotein
mass
ratio
first
digest
overnight
trypsintoprotein
mass
ratio
second
hdigest
peptid
label
differ
tmt
tag
label
sampl
mix
desalt
dri
vacuum
centrifug
fraction
highph
reversephas
hplc
use
thermo
betasil
column
tryptic
peptid
dissolv
formic
acid
solvent
directli
load
onto
homemad
reversephas
analyt
column
length
id
gradient
compris
increas
solvent
b
formic
acid
acetonitril
min
increas
min
climb
min
concentr
held
last
min
step
perform
constant
flow
rate
nlmin
easynlc
ultraperform
liquid
chromatographi
uplc
system
peptid
subject
nanoelectrospray
ioniz
nsi
sourc
follow
tandem
mass
spectrometri
msm
q
plu
instrument
thermo
coupl
onlin
uplc
appli
electrospray
voltag
kv
mz
scan
rang
full
scan
intact
peptid
detect
orbitrap
resolut
peptid
select
msm
use
normal
collis
energi
nce
set
fragment
detect
orbitrap
resolut
datadepend
procedur
altern
one
ms
scan
msm
scan
dynam
exclus
use
automat
gain
control
agc
set
fix
first
mass
set
mz
cell
treat
dmso
h
prior
infect
tgev
moi
h
total
rna
cell
extract
use
trizol
reagent
invitrogen
grand
island
ny
hpi
respect
cdna
gener
use
revertra
ace
qpcr
rt
kit
toyobo
japan
accord
manufactur
instruct
quantit
realtim
pcr
perform
use
sybr
green
biorad
n
gene
express
calcul
use
rel
quantif
model
normal
intern
control
gapdh
primer
target
tgev
n
protein
gapdh
follow
tgev
nspecif
primer
forward
revers
ctggtc
gapdhspecif
primer
forward
revers
specif
pig
sirna
sequenc
obtain
publish
paper
gan
et
al
synthes
genepharma
shanghai
china
nc
sirna
purchas
genepharma
sequenc
sirna
sequenc
sirna
transfect
perform
transfect
reagent
accord
manufactur
instruct
effici
sirna
character
western
blot
proport
target
protein
calcul
use
imagej
softwar
cell
transfect
sirna
nc
sirna
h
cell
infect
moi
tgev
treat
h
infect
moi
tgev
cell
treat
tgev
dmso
h
post
transfect
use
control
viru
yield
supernat
cultur
detect
plaqu
assay
cell
cultur
sixwel
plate
mockinfect
infect
tgev
moi
indic
post
infect
time
cell
harvest
lysi
buffer
beyotim
china
contain
proteas
inhibitor
boil
min
sampl
load
buffer
beyotim
china
sampl
fraction
sdspage
gel
transfer
onto
polyvinyliden
difluorid
pvdf
merck
millipor
usa
block
bovin
serum
albumin
dri
skim
milk
tb
mm
trishcl
ph
mm
nacl
room
temperatur
h
incub
indic
primari
antibodi
wash
three
time
membran
expos
speciesspecif
horseradish
peroxidaseconjug
secondari
antibodi
anoth
h
wash
three
time
follow
enhanc
chemiluminesc
ecl
thermo
scientif
detect
autoradiographi
biorad
gapdh
use
load
control
experi
perform
triplic
data
present
mean
standard
deviat
sd
differ
mean
analyz
student
ttest
p
valu
less
consid
statist
signific
p
p
p
achiev
robust
signal
highthroughput
screen
ht
cell
number
moi
assay
endpoint
optim
meet
condit
sb
cv
screen
librari
pharmacolog
activ
compound
antitgev
activ
optim
condit
use
cpebas
ht
assay
two
compound
flunarizin
exert
strong
inhibitori
effect
tgev
replic
vitro
structur
shown
fig
elimin
cytotox
effect
cell
viabil
variou
concentr
flunarizin
evalu
use
mtt
assay
fig
ribavirin
previous
report
inhibit
merscov
replic
falzarano
et
al
thu
use
posit
control
compar
dmso
control
flunarizin
ribavirin
cytotox
cell
concentr
respect
fig
subsequ
mtt
assay
show
cytotox
fig
compar
antivir
potenc
cell
infect
tgev
moi
treat
dmso
compound
variou
concentr
viru
yield
supernat
determin
hpi
fig
e
compar
vehicl
control
dmso
ribavirin
display
dosedepend
inhibitori
activ
tgev
cell
inhibit
observ
treat
cell
flunarizin
concentr
cytotox
note
strong
viral
inhibit
produc
flunarizin
might
due
cytotox
concentr
fig
base
cytotox
antivir
efficaci
result
chose
evalu
studi
taken
togeth
initi
studi
identifi
specif
rtki
strongli
suppress
tgev
yield
explor
whether
antivir
activ
affect
cell
type
virustocel
ratio
viral
inhibit
assay
perform
epitheli
fibroblast
deriv
cell
type
variou
moi
st
cell
treat
vehicl
control
dmso
infect
tgev
moi
peak
tgev
replic
differ
moi
observ
variou
time
point
viral
yield
supernat
quantifi
h
moi
h
moi
h
moi
post
infect
shown
fig
b
strongli
inhibit
tgev
product
two
cell
line
test
virustocel
ratio
although
variat
cell
type
observ
addit
log
decreas
infecti
progeni
observ
treatment
group
compar
dmso
treatment
control
taken
togeth
result
demonstr
inhibit
tgev
replic
limit
singl
cell
type
effect
even
rel
high
level
input
viru
compar
behavior
st
cell
display
greater
inhibit
tgev
cell
one
explan
differ
may
uptak
differ
per
cell
line
determin
specif
step
tgev
life
cycl
inhibit
perform
timeofaddit
assay
cell
treat
h
tgev
infect
h
time
infect
h
h
posttgev
infect
h
fig
tgev
infect
cell
treat
dmso
control
titer
infecti
viral
particl
supernat
hpi
measur
plaqu
assay
ad
either
h
viru
infect
display
rel
slight
inhibitori
activ
tgev
infect
fig
suggest
low
effect
viru
bind
entri
addit
signific
decreas
viru
yield
compar
dmsotreat
control
ad
tgev
attach
interestingli
ad
h
post
tgev
infect
viru
yield
reduc
log
find
indic
mainli
block
postadsorpt
stage
tgev
life
cycl
addit
inhibitori
effect
like
exert
cellular
mechan
rather
directli
reduc
virion
infect
investig
whether
tgev
inhibitor
potenti
broadspectrum
cov
inhibitor
assess
activ
three
addit
cov
betacoronaviru
mhv
strain
alphacoronavirus
fipv
pedv
initi
cell
viabil
assay
verifi
result
sign
toxic
cell
concentr
data
shown
cell
treat
dmso
follow
infect
viru
moi
cell
supernat
harvest
hpi
mhv
cell
hpi
fipv
cell
hpi
pedv
cell
titrat
plaqu
assay
fig
dose
use
pedv
progeni
titer
decreas
log
fipv
mhv
product
reduc
similar
extent
reduct
respect
overal
result
demonstr
display
cov
inhibitori
activ
inhibit
infecti
pedv
mhv
fipv
similar
potenc
explor
downstream
mechan
might
regul
cellular
anticoronavir
respons
perform
compar
proteom
analysi
identifi
chang
phosphoryl
statu
use
tmtlabel
quantit
lcmsm
approach
cell
subject
four
differ
experi
mock
control
untreat
treat
tgevinfect
cell
tgevinfect
tgev
infect
treatment
three
biolog
replic
combin
total
phosphosit
correspond
phosphoryl
protein
identifi
phosphoproteom
analysi
among
group
n
group
phosphoryl
protein
quantifi
tabl
protein
met
criteria
p
foldchang
ratio
consid
differenti
regul
phosphoprotein
drp
phosphoprotein
phosphoprotein
significantli
upregul
downregul
tgevinfect
group
rel
untreat
control
fig
tabl
among
protein
increas
proteom
background
nuclearencod
mitochondri
protein
fig
tabl
moreov
level
phosphoryl
significantli
upregul
respect
without
chang
overal
protein
express
tgev
infect
sampl
compar
mock
control
fig
tabl
contrast
treatment
reduc
phosphoryl
tgevinfect
cell
fig
c
tabl
treatment
alon
affect
overal
express
phosphoryl
statu
rel
untreat
control
tabl
surprisingli
comparison
group
mock
control
group
show
phosphoryl
status
multipl
protein
markedli
increas
treatment
includ
elong
factor
tu
tufm
ribosom
protein
efhand
domaincontain
protein
deltalik
protein
addit
phosphosign
fourteen
protein
decreas
significantli
cell
compar
untreat
control
cell
fig
tabl
overal
result
reveal
strong
correl
tgev
andor
gain
insight
biolog
relev
function
chang
protein
phosphoryl
tgev
infect
subsequ
treatment
enrich
chang
phosphoryl
gene
ontolog
go
term
function
categori
data
repres
averag
least
three
independ
experi
error
bar
indic
standard
deviat
statist
analysi
perform
use
student
ttest
p
p
assess
shown
fig
tabl
protein
exhibit
differenti
phosphoryl
treatment
associ
variou
biolog
process
includ
cell
growth
energi
pathway
cell
commun
protein
metabol
signal
transduct
investig
pathway
affect
tgev
infect
subsequ
treatment
result
indic
activ
sever
kinasemedi
signal
pathway
increas
fig
tabl
pathway
includ
signal
event
mapk
pathway
also
util
motifx
onlin
softwar
version
http
motifxmedharvardedu
assess
enrich
signific
motif
substrat
treatment
result
identif
three
tyrosinebas
phosphoryl
motif
sequenc
yxxxr
kxxxxi
yxxxxk
accord
result
significantli
phosphoryl
amino
acid
tyrosin
follow
threonin
yxxxrxx
also
signific
kinas
motif
consist
properti
inhibitor
rtk
fig
tabl
furthermor
two
phosphomotif
yxxxr
kxxxxi
enrich
tgev
infect
fig
tabl
indic
significantli
phosphoryl
amino
acid
tgev
infect
tyrosin
motif
identifi
found
mani
protein
kinas
mapk
famili
substrat
addit
tp
enrich
threonin
motif
substrat
commonli
bind
kinas
fig
tabl
motif
analysi
along
result
overrepresent
phosphoprotein
predict
substrat
mapk
support
increas
activ
tgev
infect
protein
network
relat
phosphoprotein
assembl
ingenu
pathway
analysi
ipa
version
drp
recogn
map
predict
network
fig
tabl
mapk
famili
especi
found
import
node
interact
mani
protein
predict
play
import
role
interact
network
phosphoryl
level
increas
decreas
tgev
infect
subsequ
treatment
mention
interact
network
offer
clue
elucid
pathogen
mechan
tgev
verifi
drp
identifi
phosphoproteom
analysi
examin
lysat
tgevinfect
cell
western
blot
phosphospecif
antibodi
tgevinfect
cell
level
phosphoryl
increas
hpi
hpi
chang
detect
total
amount
progress
tgev
infect
uninfect
cell
phosphoryl
status
weak
unchang
hpi
hpi
addit
level
total
protein
consist
tgevinfect
cell
rel
high
level
addit
phosphoryl
statu
follow
tgev
infect
accord
result
phosphoproteom
analysi
result
show
infect
cell
tgev
activ
jnk
signal
evidenc
increas
phosphoryl
level
fig
b
investig
relationship
among
andor
tgev
infect
assess
phosphoryl
overal
express
level
tgevinfect
cell
cell
receiv
treatment
western
blot
cell
infect
tgev
moi
treat
dmso
cell
lysat
collect
hpi
immunoblot
shown
fig
phosphoryl
upregul
tgevinfect
cell
dmso
treatment
alter
upregul
phosphoryl
induc
tgev
infect
contrast
increas
phosphoryl
induc
tgev
infect
dramat
reduc
treatment
total
protein
level
equival
differ
treatment
group
identifi
exhibit
increas
phosphoryl
upon
tgev
infect
treatment
cell
result
downregul
phosphoryl
tgevinfect
cell
perform
western
blot
measur
phosphoryl
overal
express
level
tgevinfect
cell
moi
cell
receiv
treatment
shown
fig
dramat
reduc
phosphoryl
induc
tgev
infect
explor
whether
affect
tgev
replic
inhibit
downstream
mediat
jnk
mapk
pathway
treat
tgevinfect
cell
specif
inhibitor
determin
toxic
inhibitor
cell
use
mtt
assay
concentr
less
less
toxic
test
cell
data
shown
cell
also
pretreat
differ
concentr
inhibitor
h
prior
infect
infect
tgev
moi
viru
titer
determin
hpi
plaqu
assay
shown
fig
inhibitor
reduc
tgev
replic
dose
depend
manner
compar
dmso
treat
control
cell
inhibitori
effect
two
inhibitor
significantli
differ
mark
inhibit
observ
contrast
viru
titer
slightli
reduc
treatment
even
concentr
maxim
antivir
effect
observ
without
cytotox
find
suggest
might
effect
inhibit
tgev
propag
examin
kinet
tgev
growth
cell
presenc
inhibitor
dmso
result
show
overal
process
tgev
replic
markedli
delay
cell
treat
respect
optim
concentr
fig
interestingli
found
amount
tgev
releas
medium
significantli
reduc
hpi
hpi
treatment
contrast
viru
yield
affect
treatment
hpi
hpi
inhibitori
effect
viru
propag
rel
weaker
suggest
activ
play
import
role
viral
life
cycl
examin
effect
viral
rna
synthesi
protein
synthesi
tgevinfect
cell
cultur
presenc
dmso
cell
collect
differ
time
point
post
infect
level
n
gene
quantifi
shown
fig
mrna
abund
approxim
lower
hpi
cell
treat
cell
treat
dmso
alon
treat
group
show
reduct
tgev
n
mrna
level
fold
result
indic
viral
rna
synthesi
significantli
inhibit
amount
viral
structur
protein
n
also
clearli
reduc
cell
compar
dmsotreat
cell
show
much
greater
effect
demonstr
inhibit
synthesi
tgev
protein
fig
result
accord
n
mrna
express
data
togeth
find
suggest
mapk
signal
pathway
requir
effici
tgev
replic
final
essenti
regulatori
role
tgev
infect
valid
use
second
inhibitor
determin
toxic
cell
use
mtt
assay
found
concentr
less
toxic
test
cell
data
shown
tgevinfect
cell
treat
inhibitor
determin
viru
titer
plaqu
assay
hpi
overal
data
demonstr
significantli
reduc
tgev
replic
fig
also
evalu
tgev
growth
kinet
cell
presenc
result
similar
result
report
overal
process
tgev
replic
markedli
delay
cell
treat
fig
use
sirnamedi
knockdown
address
whether
inhibit
tgev
replic
target
downstream
mediat
cell
transient
transfect
sirna
target
neg
control
nc
sirna
h
sirna
target
appar
reduc
express
determin
western
blot
fig
next
cell
plate
transfect
sirna
nc
sirna
h
prior
infect
tgev
moi
viru
yield
determin
plaqu
assay
differ
time
point
post
infect
compar
nc
sirna
sirna
target
markedli
decreas
viral
titer
log
fig
hpi
specif
also
test
nc
sirna
transfect
cell
cell
infect
tgev
cell
transfect
sirna
nc
sirna
h
treat
moi
tgev
h
cell
treat
tgev
dmso
transfect
sirna
use
control
viru
yield
supernat
hpi
detect
plaqu
assay
interestingli
differ
inhibitori
activ
tgev
observ
cell
nc
sirnatransfect
cell
fig
collect
result
indic
target
inhibit
tgev
replic
lopac
collect
high
qualiti
innov
druglik
molecul
use
broad
rang
studi
includ
cell
signal
neurosci
reflect
commonli
screen
target
drug
discoveri
commun
studi
lopac
use
screen
anticov
drug
use
tgev
surrog
model
cov
success
ht
new
antivir
drug
candid
identifi
confirm
promin
novel
inhibitor
tgev
addit
inhibit
infecti
pedv
mhv
fipv
replic
similar
potenc
fig
kumar
et
al
shown
two
smallmolecul
rtki
potent
block
influenza
viru
replic
multipl
step
viral
life
cycl
antiinfluenza
activ
may
due
suppress
trka
signal
precis
inhibitori
mechan
remain
unknown
kumar
et
al
kumar
et
al
effect
tgev
replic
underli
mechan
vitro
explor
present
studi
effect
replic
viru
depend
host
cell
machineri
similar
virus
cov
modul
sever
cellular
pathway
enhanc
replic
regul
phosphoryl
dephosphoryl
host
protein
also
case
pedv
sarscov
mhv
merscov
banerje
et
al
kim
lee
tgev
activ
mapk
signal
pathway
cultur
cell
lysat
untreat
control
tgevinfect
cell
indic
time
subject
sdspage
immunoblot
use
antibodi
phosphoryl
total
phosphoryl
jnk
total
jnk
tgev
n
protein
c
e
activ
abolish
treatment
cell
treat
dmso
follow
tgev
infect
moi
untreat
cell
use
mock
control
lysat
cell
collect
hpi
analyz
immunoblot
use
indic
antibodi
gapdh
detect
verifi
equal
load
kindrachuk
et
al
lee
et
al
mizutani
et
al
nevertheless
studi
date
focus
detect
global
phosphoryl
event
host
cell
cov
infect
rtki
hypothes
antivir
effect
like
influenc
phosphoryl
molecul
downstream
rtk
cell
requir
viral
replic
studi
appli
quantit
phosphoproteom
analysi
assess
chang
cellular
phosphoprotein
involv
host
respons
tgev
infect
phosphoprotein
cell
three
viral
protein
matrix
protein
spike
glycoprotein
nucleoprotein
identifi
tabl
motif
analysi
suggest
significantli
phosphoryl
amino
acid
tgev
infect
tyrosin
fig
consist
act
inhibitor
rtk
inhibit
replic
tgev
sever
cov
n
protein
shown
phosphoryl
phosphoryl
site
tgev
avian
infecti
bronchiti
viru
ibv
mhv
n
protein
identifi
calvo
et
al
chen
et
al
white
et
al
chen
colleagu
report
phosphoryl
ibv
n
protein
present
higher
affin
viral
rna
nonvir
rna
chen
et
al
phosphoryl
also
play
import
role
immunoreact
specif
sar
n
protein
shin
et
al
phosphoryl
statu
ibv
n
protein
greatest
impact
initi
rescu
infecti
viru
cdna
spencer
et
al
phosphoryl
modif
uniqu
strategi
cov
n
facilit
synthesi
longer
viral
rna
subsequ
viral
progeni
product
recruit
cellular
wu
et
al
howev
function
phosphoryl
cov
n
protein
viral
pathogenesi
unknown
investig
need
determin
whether
spike
glycoprotein
matrix
protein
could
phosphoryl
cov
infect
well
mechan
coronavir
protein
phosphoryl
function
viral
replic
studi
first
reveal
global
phosphoryl
event
cell
induc
tgev
infect
use
quantit
phosphoproteom
may
therefor
provid
basi
better
understand
molecular
mechan
tgev
pathogenesi
addit
assist
develop
antivir
drug
target
tgev
sever
studi
indic
mani
downstream
target
rtk
involv
cov
replic
yang
et
al
found
pedv
infect
stimul
activ
egfr
downstream
cascad
increas
viral
infect
neg
regul
type
interferon
ifni
signal
yang
et
al
erkmapk
signal
respons
play
import
role
merscov
infect
kindrachuk
et
al
jnk
phosphatidylinositol
akt
requir
establish
persist
sarscov
infect
vero
cell
mizutani
et
al
phosphoproteom
analysi
found
tgev
infect
enhanc
inhibitortr
dmsotreat
cell
infect
tgev
moi
h
cultiv
presenc
inhibitor
dmso
viral
rna
level
quantifi
indic
time
realtim
rtpcr
normal
intern
control
pig
gapdh
mrna
chemic
inhibit
activ
impair
viral
protein
synthesi
western
blot
analysi
viral
n
protein
indic
time
cell
infect
tgev
moi
treat
dmso
inhibitor
gapdh
detect
use
confirm
equal
load
valu
present
mean
three
independ
experi
error
bar
indic
sd
statist
analysi
conduct
student
ttest
p
p
p
phosphoryl
respect
tgevinfect
cell
compar
untreat
control
cell
fig
b
fig
tabl
addit
activ
cell
expos
uvinactiv
tgev
data
shown
result
indic
activ
jnk
mapk
due
actual
replic
viru
cell
howev
tyrphostin
treatment
block
tgevinduc
phosphoryl
fig
e
tabl
indic
jnk
map
kinas
function
downstream
rtk
explor
effect
downstream
mediat
rtk
tgev
replic
use
specif
inhibitor
respect
result
show
pretreat
significantli
reduc
tgev
n
mrna
protein
level
fig
lower
tgev
titer
fig
b
compar
dmsotreat
control
cell
specul
inhibitori
activ
tgev
replic
might
target
multipl
host
kinas
downstream
rtk
rtk
primari
mediat
mani
signal
control
mani
downstream
cascad
includ
phosphoinositid
mapk
pathway
schlessing
sever
studi
shown
phosphoinositid
signal
cascad
downstream
rtk
play
import
role
life
cycl
cov
hu
et
al
kindrachuk
et
al
mizutani
et
al
yang
et
al
studi
requir
explor
whether
downstream
cascad
involv
inhibitori
activ
tgev
replic
extent
might
target
multipl
host
compon
drugresist
viral
variant
less
like
occur
kumar
et
al
result
show
inhibitori
effect
viru
propag
rel
weaker
fig
correl
suggest
mainli
inhibit
replic
tgev
pathway
also
use
anoth
inhibitor
valid
essenti
regulatori
role
tgev
infect
result
consist
significantli
reduc
tgev
replic
fig
f
also
perform
rna
interfer
valid
play
import
regulatori
role
tgev
replic
fig
b
level
express
reduc
fig
residu
would
still
phosphoryl
tgev
infect
promot
viru
replic
moreov
pathway
also
play
role
tgev
replic
treatment
jnk
signal
pathway
fig
therefor
inhibitori
effect
sirna
strong
effect
inhibitor
viral
replic
furthermor
specif
test
wild
type
cell
tgev
infect
interestingli
inhibitori
activ
tgev
cell
similar
nc
sirnatransfect
cell
fig
result
suggest
inhibit
tgev
replic
mainli
via
target
mapk
import
cellular
signal
molecul
regul
cell
growth
apoptosi
metabol
differenti
normal
patholog
condit
well
character
mapk
compos
three
major
group
extracellular
signalregul
kinas
also
known
mapk
map
kinas
jnk
schaeffer
weber
mapk
pathway
activ
varieti
cov
play
crucial
role
cov
infect
report
pedv
infect
activ
mapk
exploit
molecul
optim
replic
lee
et
al
addit
mhv
infect
activ
mapk
jnk
necessari
replic
banerje
et
al
activ
mapk
fipv
regul
proinflammatori
cytokin
product
key
contributor
patholog
chang
observ
cat
fip
regan
et
al
mapk
activ
requir
human
cov
replic
chloroquin
inhibit
replic
may
suppress
activ
kono
et
al
find
show
mainli
inhibit
tgev
replic
pathway
moreov
inhibit
infecti
pedv
mhv
fipv
replic
similar
potenc
henc
reason
specul
may
inhibit
replic
cov
mechan
similar
find
tyrphostin
treatment
inhibit
phosphoryl
anand
et
al
although
effect
mapk
viral
replic
studi
varieti
virus
littl
known
mechan
activ
facilit
viru
replic
author
one
studi
discuss
stimul
mapk
may
enhanc
transcript
specif
viral
gene
promot
lead
promot
herp
simplex
viru
type
prolifer
zacho
et
al
mhv
mapk
activ
result
phosphoryl
facilit
viru
protein
synthesi
subsequ
product
infecti
viru
banerje
et
al
cencic
et
al
report
target
complex
strategi
block
cov
infect
cencic
et
al
downstream
molecul
mapk
fig
one
target
inhibitori
activ
tgev
replic
effici
sirna
evalu
western
blot
cell
plate
transfect
indic
sirna
pmol
use
transfect
reagent
h
post
transfect
cell
lyse
subject
western
blot
antibodi
protein
level
quantifi
imagej
softwar
normal
amount
gapdh
b
knock
express
sirna
inhibit
tgev
replic
hpi
cell
plate
transfect
sirna
nc
sirna
pmol
respect
h
post
transfect
cell
infect
moi
tgev
viru
yield
supernat
cultur
measur
differ
time
point
use
plaqu
assay
c
effect
downregul
mapk
inhibitori
activ
tgev
replic
cell
transfect
sirna
nc
sirna
h
treat
moi
tgev
h
cell
treat
tgev
dmso
h
post
transfect
use
control
viru
yield
supernat
cultur
detect
plaqu
assay
data
shown
mean
three
independ
experi
b
c
statist
analys
use
student
ttest
p
p
p
increas
phosphoryl
usual
lead
enhanc
translat
rate
gingra
et
al
result
show
tgevspecif
protein
synthesi
decreas
infect
cell
treat
fig
therefor
whether
viral
replic
enhanc
mapk
modul
downstream
molecul
increas
viral
protein
synthesi
tgevinfect
cell
remain
determin
tgev
infect
induc
high
level
map
kinas
phosphoryl
requir
tgev
replic
inhibitor
rtk
initi
signal
cascad
involv
phosphoryl
tyrosin
kinas
turn
inhibit
phosphoryl
activ
tgev
infect
result
robust
decreas
tgev
replic
conclus
although
signal
intermedi
tgev
rtk
remain
elucid
identifi
valid
mapk
main
downstream
signal
node
inhibitori
activ
tgev
replic
find
report
provid
novel
insight
molecular
mechan
underli
tgev
replic
offer
new
promis
therapeut
possibl
combat
infect
caus
cov
summari
find
show
tgev
infect
stimul
phosphoryl
treatment
attenu
phosphoryl
statu
result
decreas
tgev
replic
signific
progress
clinic
preclin
studi
rtki
anticanc
therapi
recent
year
may
promot
develop
compound
use
antivir
therapi
mass
spectrometri
proteom
data
deposit
proteomexchang
consortium
via
pride
partner
repositori
dataset
identifi
author
declar
conflict
interest
